Published • loading... • Updated
US FDA approves Revolution Medicines' pancreatic cancer drug
In a 500-patient trial, the pill nearly doubled median survival to 13.2 months and reduced death risk by 60%, researchers said.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
Insights by Ground AI
Podcasts & Opinions
180 Articles
180 Articles
The United States on Wednesday approved a drug, Rasonque, considered by experts to be the most significant advance ever in the fight against pancreatic cancer. This tablet treatment will extend the lives of patients.
·Issy-les-Moulineaux, France
Read Full Article
Developed by the American start-up Revolution Medicines, this medicine is called Rasonque and can be taken as tablets.
Coverage Details
Total News Sources180
Leaning Left32Leaning Right20Center90Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 23%
C 63%
14%
Factuality
To view factuality data please Upgrade to Premium
